OPTISON
Details
- Status
- Prescription
- First Approved
- 1997-12-31
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
OPTISON Approval History
What OPTISON Treats
12 indicationsOPTISON is approved for 12 conditions since its original approval in 1997. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypovolemia
- Ascites
- Hypoalbuminemia
- Burns
- Acute Nephrosis
- Acute Respiratory Distress Syndrome
- Cardiopulmonary Bypass
- Liver Cirrhosis
Drugs Similar to OPTISON
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
OPTISON FDA Label Details
ProIndications & Usage
FDA Label (PDF)ALBUMINEX 25% is a 25% albumin solution indicated for adults and children : Hypovolemia Ascites Hypoalbuminemia including from burns Acute Nephrosis Acute Respiratory Distress Syndrome (ARDS) Cardiopulmonary Bypass 1.1 Hypovolemia ALBUMINEX 25% is indicated for restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate e.g. hypovolemia following shock due to trauma or sepsis, in surgical patients and in other similar conditions with volume deficiency when restoration and maintenance of circulating blood volume is r...
OPTISON Patents & Exclusivity
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.